Go to Top

COMUNICADO DE PRENSA

VEXIM SA to Host Key Opinion Leader Meeting and Webcast on October 24 in New York City

INVITATION
Toulouse, October 21st, 2014 – VEXIM (FR0011072602 – ALVXM / Eligible PEA-PME), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announced that it will host a Key Opinion Leader breakfast on Friday, October 24, 2014 from 8am-9:30am Eastern Time in New York City.
VEXIM SA to Host Key Opinion Leader Meeting and Webcast on October 24 in New York City
The meeting will feature Pr. David …Lire plus

VEXIM postpones its private placement

Toulouse, June 5th 2013 ‐ VEXIM (FR0011072602 – ALVXM), a medical device company specializing in the minimallyinvasive treatment of vertebral fractures, has today decided to postpone the private placement announced on June 3rd, as the expected conditions for its execution were not met. VEXIM was considering this private placement as a means to finance the acceleration of its clinical and commercial development.
Vincent Gardès, CEO of VEXIM, states: “In view of …Lire plus

VEXIM launches a private placement of circa €5 million

Toulouse, June 3rd 2013 ‐ VEXIM (FR0011072602 – ALVXM), a medical device company specializing in the minimallyinvasive treatment of vertebral fractures (the “Company”), today announces the launch of a capital increase without preferential subscription rights via a private placement, in accordance with the 17th resolution of the General Meeting held on March 19th 2012, for an amount of circa €5 million, within the limit of 20% of capital, i.e. a …Lire plus

2012 annual results

Toulouse, March 19th 2013 ‐ VEXIM (FR0011072602 ‐ ALVXM), a medical device companyspecializing in the minimally‐invasive treatment of vertebral fractures, today announced its consolidated annual results1 to December 31st 2012.

Acceleration in SpineJack® sales
Buoyant sales growth: +125% to €2.7m
Substantial increase in the gross margin: +5 pp to 63% of sales
Cash position at December 31st 2012: €7.5m

2013 outlook

Acceleration in marketing and clinical development
Extension of the product portfolio via a unique acquisition in …Lire plus